Christine A. Nash, M.B.A.
About Christine A. Nash, M.B.A.
Independent director at Rallybio (RLYB) since April 2022 with deep commercial leadership in rare-disease biotech. Principal at Chatiemac Consulting since April 2018; previously SVP & Chief Commercial Officer at Hyperion Therapeutics (2012–2015) and commercial roles at CoTherix (2004–2007). Holds an M.B.A. and B.A. with Honors in Public Policy from Stanford University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Chatiemac Consulting, LLC | Principal | Apr 2018–present | Strategic/commercial planning for rare-disease biotech and investors |
| The CM Group | Board Chair; Senior Advisor to President/CEO; Director | Director: Aug 2019–Sep 2022; Chair/Advisor: Sep 2021–Sep 2022 | Integrated healthcare agency; commercialization strategy for life sciences |
| Hyperion Therapeutics, Inc. | SVP & Chief Commercial Officer | May 2012–2015; rising roles since 2007 | Oversaw commercial organizations and product launches |
| CoTherix, Inc. | Commercial roles | 2004–2007 | Increasing responsibility in commercial organization |
| Genesoft; Oncology Therapeutics Network; Eli Lilly; Imana | BD/product planning/commercial roles | Various | Early commercial and BD experience |
External Roles
| Organization | Role | Type | Dates |
|---|---|---|---|
| Chatiemac Consulting, LLC | Principal | Private consulting | Apr 2018–present |
| The CM Group | Board Chair; Senior Advisor; Director | Private company | Aug 2019–Sep 2022 (director); Sep 2021–Sep 2022 (chair/advisor) |
Board Governance
- Committee assignments (current): Chair, Nominating & Corporate Governance (NCG); Member, Compensation Committee. Appointed as NCG Chair and member in March 2025 .
- Independence: Board states all members of the Compensation Committee and NCG Committee (including Nash) are independent under Nasdaq/Rule 10C-1 .
- Committee activity (FY 2024): Compensation Committee met 5 times; NCG Committee met 1 time .
- Years of service: Board member since April 2022; initially appointed to the Compensation Committee at that time .
- Committee charters: Board maintains Audit, Compensation, and NCG committees under written charters reviewed periodically .
Fixed Compensation
| Year | Fees Earned or Paid in Cash ($) | Notes |
|---|---|---|
| 2023 | 45,000 | Non-employee director cash retainer; directors may elect to receive retainer as stock options per policy (see below) |
| 2024 | 45,000 | Non-employee director cash retainer; same election policy applies |
- Director compensation policy: Non-employee directors may elect to receive the annual cash retainer in the form of an option to purchase common stock, granted Jan 2 (2023/2024), vesting in 12 equal monthly installments through the calendar year; grant-date fair value per ASC 718; board describes assumptions in Note 7 to the 10-Ks .
Performance Compensation
| Year | Award Type | Grant Date | Grant-Date Fair Value ($) | Vesting/Structure |
|---|---|---|---|---|
| 2023 | Annual stock options | May 2023 | 63,950 | ASC 718 valuation; vesting terms per standard director option grant (company policy) |
| 2024 | Annual stock options | May 2024 | 23,981 | ASC 718 valuation; vesting terms per standard director option grant (company policy) |
- Performance metrics tied to director pay: Not disclosed; director compensation comprises cash retainers and equity options, with optional retainer delivery in options and annual option grants .
Other Directorships & Interlocks
- Public company directorships: None disclosed for Nash in RLYB proxy biographies .
- Interlocks/conflicts: 13D/A and beneficial ownership footnotes discuss Pivotal/Nan Fung group ties via director Rob Hopfner; no such disclosures for Nash .
- Appointment context: No arrangements/understandings pursuant to which Nash was elected; no material related-party transactions under Item 404(a) at appointment .
Expertise & Qualifications
- Education: M.B.A. and B.A. with Honors in Public Policy from Stanford University .
- Domain expertise: Extensive operational and business experience in pharma/biotech, executive leadership, commercialization and product launches in rare diseases .
- Governance competencies: As NCG Chair, oversees board composition, evaluations, governance principles, ESG oversight and disclosure .
Equity Ownership
| Measure | 2023 (as of Dec 31) | 2024 (as of Dec 31) | 2025 (exercisable within 60 days of Mar 31) |
|---|---|---|---|
| Stock options held (#) | 44,610 | 61,110 | 61,110 |
| Unvested restricted stock awards (#) | 0 (none) | 0 (none) | — |
| Notes | No unvested RSAs; option grants per director program | No unvested RSAs; option grants per director program | Footnote confirms options exercisable within 60 days |
- Pledging/hedging: No pledging or hedging disclosures specific to Nash found in cited documents.
- Ownership guidelines: Compensation Committee may recommend stock ownership guidelines for directors; specific multiples not disclosed .
Governance Assessment
-
Positive signals: Elevation to Chair of NCG in Mar 2025 enhances board refreshment, evaluation, ESG oversight, and conflict review; both NCG and Compensation Committees composed solely of independent directors, supporting governance quality .
-
Alignment: Consistent option-based equity grants and meaningful option holdings (61,110 options exercisable within 60 days) provide equity exposure; no RSAs and no related-party transactions at appointment reduce conflict risk .
-
Engagement: Committee meeting cadence in 2024 (NCG: 1; Comp: 5) indicates active involvement in compensation and governance matters; specific board/committee attendance rates for Nash are not disclosed in available RLYB filings .
-
RED FLAGS: None identified in filings—no Item 404(a) related-party transactions, no RSU overhang for Nash, and no pledging disclosures specific to Nash .
